About novo nordisk a/s - NVO
NVO At a Glance
| Phone | 45-44-44-88-88 | Revenue | 42.12B | |
| Industry | Pharmaceuticals: Major | Net Income | 14.65B | |
| Sector | Health Technology | 2024 Sales Growth | 24.969% | |
| Fiscal Year-end | 12 / 2025 | Employees | 76,302 | |
| View SEC Filings |
NVO Valuation
| P/E Current | 22.004 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 26.159 |
| Price to Sales Ratio | 9.116 |
| Price to Book Ratio | 19.173 |
| Price to Cash Flow Ratio | 21.884 |
| Enterprise Value to EBITDA | 18.388 |
| Enterprise Value to Sales | 9.368 |
| Total Debt to Enterprise Value | 0.036 |
NVO Efficiency
| Revenue/Employee | 551,951.474 |
| Income Per Employee | 191,941.803 |
| Receivables Turnover | 4.055 |
| Total Asset Turnover | 0.757 |
NVO Liquidity
| Current Ratio | 0.74 |
| Quick Ratio | 0.552 |
| Cash Ratio | 0.121 |
NVO Profitability
| Gross Margin | 83.848 |
| Operating Margin | 48.003 |
| Pretax Margin | 43.804 |
| Net Margin | 34.775 |
| Return on Assets | 26.322 |
| Return on Equity | 82.014 |
| Return on Total Capital | 42.827 |
| Return on Invested Capital | 57.199 |
NVO Capital Structure
| Total Debt to Total Equity | 71.636 |
| Total Debt to Total Capital | 41.737 |
| Total Debt to Total Assets | 22.067 |
| Long-Term Debt to Equity | 62.497 |
| Long-Term Debt to Total Capital | 36.412 |
Novo Nordisk A/S in the News
Novo Nordisk CEO steps down as Wegovy maker faces increased competition
As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.
Hims & Hers partners with Novo Nordisk to sell Wegovy
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Pfizer will end development of daily weight-loss pill after liver injury
Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the drug after liver issues affected one patient.
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Running low on Ozempic or another weight loss drug? A new tracker can help
Telehealth company Ro has rolled out a new tool to track the supply of weight loss drugs like Ozempic and Wegovy across the U.S., as patients struggle with shortages.
Nestlé launches food line targeting Ozempic, other weight-loss drug users
Nestlé's new food line, Vital Pursuit, is specifically targeted toward patients using weight-loss medications, which continues to surge in popularity.
25K Americans starting Wegovy weekly as supply increases and prices drop, drugmaker says
Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week.
Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drug
Wegovy has been FDA-approved for heart disease prevention. The semaglutide, originally approved for weight loss, is now approved to reduce the risk of cardiovascular death, heart attack and stroke.
Ozempic, Wegovy and other weight loss drugs present holiday challenges
Holiday prep may include forgoing doses for some people taking medications popularly used to facilitate weight loss. Those who do that need to be careful when resuming them, an expert said.
Novo Nordisk shares fall after media report on quality lapses at US plant
Novo Nordisk, a pharmaceutical company, experienced a decline in its stock prices following a report by financial news agency MarketWire.